Logo image of DNA

GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Fundamental Analysis

USA - NYSE:DNA - US37611X2099 - Common Stock

11.37 USD
-0.05 (-0.44%)
Last: 9/19/2025, 8:04:00 PM
11.2941 USD
-0.08 (-0.67%)
After Hours: 9/19/2025, 8:04:00 PM
Fundamental Rating

4

Taking everything into account, DNA scores 4 out of 10 in our fundamental rating. DNA was compared to 55 industry peers in the Life Sciences Tools & Services industry. While DNA has a great health rating, there are worries on its profitability. DNA is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DNA had negative earnings in the past year.
In the past year DNA has reported a negative cash flow from operations.
In the past 5 years DNA always reported negative net income.
In the past 5 years DNA always reported negative operating cash flow.
DNA Yearly Net Income VS EBIT VS OCF VS FCFDNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -500M -1B -1.5B -2B

1.2 Ratios

DNA has a worse Return On Assets (-25.60%) than 74.55% of its industry peers.
DNA's Return On Equity of -51.42% is on the low side compared to the rest of the industry. DNA is outperformed by 69.09% of its industry peers.
Industry RankSector Rank
ROA -25.6%
ROE -51.42%
ROIC N/A
ROA(3y)-58.74%
ROA(5y)-56.67%
ROE(3y)-93%
ROE(5y)-85.6%
ROIC(3y)N/A
ROIC(5y)N/A
DNA Yearly ROA, ROE, ROICDNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

DNA's Gross Margin of 78.99% is amongst the best of the industry. DNA outperforms 98.18% of its industry peers.
In the last couple of years the Gross Margin of DNA has declined.
DNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.07%
GM growth 5Y-4.27%
DNA Yearly Profit, Operating, Gross MarginsDNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

7

2. Health

2.1 Basic Checks

DNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DNA has more shares outstanding
The number of shares outstanding for DNA has been reduced compared to 5 years ago.
DNA has a better debt/assets ratio than last year.
DNA Yearly Shares OutstandingDNA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
DNA Yearly Total Debt VS Total AssetsDNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

Based on the Altman-Z score of -6.40, we must say that DNA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.40, DNA is not doing good in the industry: 90.91% of the companies in the same industry are doing better.
DNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.4
ROIC/WACCN/A
WACC10.4%
DNA Yearly LT Debt VS Equity VS FCFDNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 5.41 indicates that DNA has no problem at all paying its short term obligations.
DNA's Current ratio of 5.41 is fine compared to the rest of the industry. DNA outperforms 76.36% of its industry peers.
DNA has a Quick Ratio of 5.41. This indicates that DNA is financially healthy and has no problem in meeting its short term obligations.
DNA has a Quick ratio of 5.41. This is in the better half of the industry: DNA outperforms 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 5.41
Quick Ratio 5.41
DNA Yearly Current Assets VS Current LiabilitesDNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

DNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.95%, which is quite impressive.
DNA shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.24%.
The Revenue has been growing by 33.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)65.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.71%
Revenue 1Y (TTM)25.24%
Revenue growth 3Y-10.23%
Revenue growth 5Y33.17%
Sales Q2Q%-11.75%

3.2 Future

DNA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.86% yearly.
The Revenue is expected to grow by 46.59% on average over the next years. This is a very strong growth
EPS Next Y40.12%
EPS Next 2Y20.9%
EPS Next 3Y17.78%
EPS Next 5Y14.86%
Revenue Next Year-22.25%
Revenue Next 2Y-5.68%
Revenue Next 3Y-0.63%
Revenue Next 5Y46.59%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DNA Yearly Revenue VS EstimatesDNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B
DNA Yearly EPS VS EstimatesDNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNA Price Earnings VS Forward Price EarningsDNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNA Per share dataDNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as DNA's earnings are expected to grow with 17.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.9%
EPS Next 3Y17.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GINKGO BIOWORKS HOLDINGS INC

NYSE:DNA (9/19/2025, 8:04:00 PM)

After market: 11.2941 -0.08 (-0.67%)

11.37

-0.05 (-0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)N/A N/A
Inst Owners69.01%
Inst Owner Change-14.24%
Ins Owners6.83%
Ins Owner Change0.03%
Market Cap638.99M
Analysts41.82
Price Target11.56 (1.67%)
Short Float %15.49%
Short Ratio4.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.25%
Min EPS beat(2)6.02%
Max EPS beat(2)30.48%
EPS beat(4)3
Avg EPS beat(4)22.63%
Min EPS beat(4)-11.88%
Max EPS beat(4)65.88%
EPS beat(8)5
Avg EPS beat(8)1.14%
EPS beat(12)6
Avg EPS beat(12)0.21%
EPS beat(16)6
Avg EPS beat(16)-243.94%
Revenue beat(2)2
Avg Revenue beat(2)20.83%
Min Revenue beat(2)18.03%
Max Revenue beat(2)23.63%
Revenue beat(4)3
Avg Revenue beat(4)33.8%
Min Revenue beat(4)-2.36%
Max Revenue beat(4)95.92%
Revenue beat(8)5
Avg Revenue beat(8)17.62%
Revenue beat(12)9
Avg Revenue beat(12)15.21%
Revenue beat(16)13
Avg Revenue beat(16)27.99%
PT rev (1m)30.77%
PT rev (3m)38.21%
EPS NQ rev (1m)11.85%
EPS NQ rev (3m)14.09%
EPS NY rev (1m)13.49%
EPS NY rev (3m)16.62%
Revenue NQ rev (1m)-3.42%
Revenue NQ rev (3m)-13.29%
Revenue NY rev (1m)-0.63%
Revenue NY rev (3m)-0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.77
P/FCF N/A
P/OCF N/A
P/B 1.04
P/tB 1.17
EV/EBITDA N/A
EPS(TTM)-5.72
EYN/A
EPS(NY)-4.81
Fwd EYN/A
FCF(TTM)-4.88
FCFYN/A
OCF(TTM)-4.23
OCFYN/A
SpS4.11
BVpS10.91
TBVpS9.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.6%
ROE -51.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.99%
FCFM N/A
ROA(3y)-58.74%
ROA(5y)-56.67%
ROE(3y)-93%
ROE(5y)-85.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.07%
GM growth 5Y-4.27%
F-Score5
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.99%
Cap/Sales 15.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.41
Quick Ratio 5.41
Altman-Z -6.4
F-Score5
WACC10.4%
ROIC/WACCN/A
Cap/Depr(3y)93.32%
Cap/Depr(5y)178.3%
Cap/Sales(3y)18.24%
Cap/Sales(5y)29.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.71%
EPS Next Y40.12%
EPS Next 2Y20.9%
EPS Next 3Y17.78%
EPS Next 5Y14.86%
Revenue 1Y (TTM)25.24%
Revenue growth 3Y-10.23%
Revenue growth 5Y33.17%
Sales Q2Q%-11.75%
Revenue Next Year-22.25%
Revenue Next 2Y-5.68%
Revenue Next 3Y-0.63%
Revenue Next 5Y46.59%
EBIT growth 1Y42.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.02%
EBIT Next 3Y19.17%
EBIT Next 5Y41.47%
FCF growth 1Y25.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.97%
OCF growth 3YN/A
OCF growth 5YN/A